Mortality due to COVID-19 in a Patient with Severe Asthma Receiving Omalizumab Treatment: A Case Report
ASTIM ALLERJI IMMUNOLOJI, cilt.18, ss.27-29, 2020 (ESCI, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 18
- Basım Tarihi: 2020
- Doi Numarası: 10.21911/aai.584
- Dergi Adı: ASTIM ALLERJI IMMUNOLOJI
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.27-29
- Anahtar Kelimeler: COVID-19, asthma, omalizumab, severe allergic asthma, anti-IgE, INFECTIONS
- Hacettepe Üniversitesi Adresli: Evet
Özet
Coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and caused a pandemic in the world. SARS-CoV-2 infections have a great health risk, especially in patients with chronic diseases. There are concerns that COVID-19 will be more severe in patients with severe asthma. The efficacy and safety of biological agents used in severe asthmatics during SARS-CoV-2 infections are currently unknown. In this case report, we present a patient who had been using omalizumab for five years with the diagnosis of severe asthma and died due to COVID-19. To the best of our knowledge, this is the first case of a Turkish patient who died due to COVID-19 under omalizumab treatment for severe asthma.